-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on BioNTech, Lowers Price Target to $132

Benzinga·10/14/2026 12:16:23
語音播報
Canaccord Genuity analyst John Newman maintains BioNTech (NASDAQ:BNTX) with a Buy and lowers the price target from $136 to $132.